2025-02-01 - Analysis Report
## Starbucks Corp (SBUX) Stock Performance Review

This report analyzes the performance of Starbucks Corp (SBUX), a global coffeehouse chain, comparing its returns to the S&P 500 (VOO).

**1. Performance Comparison & Alpha/Beta Analysis:**

SBUX's cumulative return is 69.03%, significantly lower than the S&P 500's 119.91%. The current divergence is -50.9%, placing it at the 30.5th percentile of its historical range (max: 49.4%, min: -95.0%).  This indicates SBUX has underperformed the market significantly over the analyzed period.

The provided Alpha/Beta analysis shows mixed results:

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) | Notes                                      |
|------------|------|------|-------|------|-------|---------------------------------------------|
| 2015-2017  | -1.0% | 5.8% | -29.0% | 0.0 | 56.2 | Significant underperformance.             |
| 2016-2018  | 2.0% | 11.9% | -17.0% | 0.3 | 64.5 | Continued underperformance.              |
| 2017-2019  | 54.0% | 11.9% | 23.0% | 1.2 | 89.8 | Strong outperformance, high beta.         |
| 2018-2020  | 79.0% | 15.3% | 52.0% | 1.0 | 111.5 |  Exceptional performance, market sensitivity. |
| 2019-2021  | 64.0% | 15.3% | -7.0% | 1.0 | 123.9 | Strong performance but lower alpha.       |
| 2020-2022  | 9.0% | 17.4% | 0.0% | 1.0 | 107.6 | Underperformed the market.                |
| 2021-2023  | -16.0% | 17.4% | -39.0% | 1.4 | 106.3 | Significant underperformance.             |
| 2022-2024  | -17.0% | 17.4% | -50.0% | 1.5 | 103.7 | Continued underperformance, high beta.    |
| 2023-2025  | -7.0% | 13.7% | -68.0% | 1.1 | 122.3 | Underperformance.                         |


While periods of strong outperformance exist, the overall trend shows significant volatility and periods of substantial underperformance compared to the S&P 500.  The beta consistently suggests a high sensitivity to market movements.


**2. Recent Price Movement:**

* **Closing Price:** $107.68
* **5-Day Moving Average:** $105.14
* **20-Day Moving Average:** $97.15
* **60-Day Moving Average:** $96.89

The price is above all moving averages, suggesting potential upward momentum, but the recent price change (-1.21) shows a minor price drop from the previous close.


**3. Technical Indicators & Expected Return:**

* **RSI:** 89.67 (Overbought territory, suggesting potential for price correction)
* **PPO:** 1.66 (Positive, indicating upward momentum)
* **Delta_Previous_Relative_Divergence:** +11.2 (Short-term upward trend)
* **Expected Return (2+ years):** -32.8% (Significant underperformance compared to S&P 500 expected over the long term).  This negative expected return, relative to the S&P 500, reinforces the underperformance observed in previous sections.  The -1.21 daily price change is a relatively minor movement and does not signal a significant correction or sharp reversal.

**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue       | Notes                                  |
|------------|------|----------------|------------------------------------------|
| 2025-01-28 | 0.69 | $9.40B         |                                          |
| 2024-07-30 | 0.93 | $9.11B         |                                          |
| 2024-04-30 | 0.68 | $8.56B         |                                          |
| 2024-01-30 | 0.90 | $9.43B         |                                          |
| 2025-01-28 | 0.90 | $9.43B         | Duplicate entry (likely a data error)   |


Revenue shows some volatility, but generally remains relatively stable around $9B. EPS shows fluctuation, with no clear upward or downward trend visible in this limited data.  The duplicate entry needs clarification.

**5. Financial Information:**

**Revenue and Profitability:**  Profit margins are generally healthy, hovering around 25-28%, demonstrating consistent profitability despite some revenue fluctuations.

**Capital and Profitability:**  Negative equity is concerning (-$7.47B to -$8.62B) and ROE is consistently negative, indicating potential financial weaknesses.  Further investigation into the causes of negative equity is necessary.


**6. Overall Conclusion:**

SBUX has demonstrated significant periods of both outperformance and underperformance relative to the S&P 500. Recent price action suggests potential upward momentum, but overbought RSI and a negative long-term expected return relative to the S&P 500 raise concerns.  The consistently negative ROE and negative equity are major red flags requiring further investigation.  While profitability margins appear healthy, the financial health of the company, as reflected by negative equity and ROE, needs to be carefully considered before making any investment decisions.  The provided data is limited; more comprehensive analysis, including a thorough examination of the negative equity, is recommended before forming a definitive opinion on SBUX's investment potential.
